Patients with histologically confirmed diagnosed with CD19 positive B cell NHL in accordance with WHO classification
Patients who are refractory to second-line treatment or patients who relapsed after first-line treatment with no available curative options such as autologous or allogeneic haematopoietic stem cell transplantation (HSCT) or relapse within one year of autologous HSCT
At least one measurable lesion according to revised IWG response criteria
Age between ≥13to ≤75 years
Adequate organ function as defined by a creatinine clearance \>40 ml/min, serum alanine transaminase (ALT) \< 5 times the normal value, serum bilirubin \< 3 times the normal value, left ventricular ejection fraction\> 45%
Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
Female of childbearing age must have a negative pregnancy test and is on two effective contraception methods
Male patients must use two effective contraception methods
You may not be if
Active central nervous system (CNS) lymphoma (detected by Imaging study or cerebrospinal fluid (CSF) analysis)
Active cancer(other than NHL) or receiving cancer treatment
Evidence of severe lung, heart (New York Heart Association class III/IV, arrhythmia, heart block, uncontrolled hypertension), liver, or renal failure or severe neurologic disorder
Presence of active autoimmune disease requiring immunosuppressive therapy
Human Immunodeficiency Virus (HIV) positivity
Active Hepatitis B, and Hepatitis C infection
Uncontrolled infection
Pregnant/nursing female.
Receiving autologous or allogeneic stem cell transplant within 12 weeks of enrolment